Literature DB >> 29398971

Incidental Detection of Asymptomatic Brain Metastases on 18F-fluoride Positron Emission Tomography/Computed Tomography and 68Ga DOTANOC Positron Emission Tomography/Computed Tomography in a Patient with Concomitant Breast Carcinoma and a Pancreatic Neuroendocrine Tumor.

Ruth Brown1, Phei Shan Chuah1, Emmanouil Panagiotidis1, Sobhan Vinjamuri1.   

Abstract

A 54-year-old female treated for locally advanced ductal breast carcinoma was also diagnosed with a pancreatic neuroendocrine tumour. A staging 68Ga DOTANOC positron emission tomography/computed tomography (PET/CT) demonstrated somatostatin receptor-positive foci within the brain parenchyma. A whole body 18F-fluoride PET/CT also demonstrated several foci of low-grade tracer uptake in the brain. Magnetic resonance imaging confirmed several cerebral and cerebellar metastases. This case highlights the need to be aware of each tumor's metastatic profile and the careful attention required for thoroughly evaluating imaging in the presence of multiple pathologies. Furthermore, such incidental findings can have significant treatment and prognostic implications.

Entities:  

Keywords:  18F-fluoride positron emission tomography/computed tomography; 68Ga DOTANOC positron emission tomography/computed tomography; brain metastases; breast carcinoma; neuroendocrine tumor

Year:  2018        PMID: 29398971      PMCID: PMC5778721          DOI: 10.4103/wjnm.WJNM_10_17

Source DB:  PubMed          Journal:  World J Nucl Med        ISSN: 1450-1147


Case Presentation

A 54-year-old female underwent two whole body positron emission tomography/computed tomography (PET/CT) scans before a gadolinium-enhanced magnetic resonance imaging (MRI) of her brain. Figure 1 shows the abnormalities found in the brain parenchyma detected by the 18F-fluoride PET/CT bone scan, which are more subtle when compared with the somatostatin receptor imaging in Figure 2, using 68Ga DOTANOC PET/CT. The two PET/CT scans were performed within a 2-week interval and demonstrate a similar pattern of tracer uptake within the brain parenchyma.
Figure 1

18F-fluoride positron emission tomography/computed tomography bone scan - abnormalities found in the brain parenchyma

Figure 2

68Ga DOTANOC positron emission tomography/computed tomography - abnormal uptake in brain parenchyma

18F-fluoride positron emission tomography/computed tomography bone scan - abnormalities found in the brain parenchyma 68Ga DOTANOC positron emission tomography/computed tomography - abnormal uptake in brain parenchyma Figures 1 and 2 both correspond to the postgadolinium MRI findings as shown in Figure 3. The histology of the neuroendocrine tumor (NET) demonstrated a Ki67 index of 4.2%, and the size of the NET reduced following the chemotherapy given for the breast cancer making it unlikely to be the source of the cerebral metastases, although brain metastases from NETs have been reported.[1] Breast cancer has a recognized predisposition to metastasize to the brain;[23] the original histology of the T3 N3, estrogen receptor negative, human epidermal receptor 2 positive invasive ductal carcinoma had a high Ki67 index of 40%, making it more likely to be the responsible primary tumor.[45] Breast cancer has been shown to express somatostatin receptors accounting for the uptake demonstrated on the 68Ga DOTANOC PET/CT.[67] In this case, there was no abnormality on the low-dose CTs that accompanied both PET scans and there was an absence of calcification in the areas of increased 18F-fluoride uptake within the brain. Extra-osseous findings including brain metastases from breast carcinoma and other primary malignancies have demonstrated uptake on 18F-fluoride PET/CT in the absence of calcification, similar to this case.[89] The patient was subsequently admitted for targeted radiotherapy to her cerebral metastases following discussion at multidisciplinary team meetings.
Figure 3

Magnetic resonance imaging confirming cerebral metastases

Magnetic resonance imaging confirming cerebral metastases

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  9 in total

1.  Extraosseus uptake of F-18 fluoride in the primary malignancy and cerebral metastasis in a case of non-small-cell lung cancer.

Authors:  Yuxin Li; Bashir A Tafti; Wisam Shaba; Gholam R Berenji
Journal:  Clin Nucl Med       Date:  2011-07       Impact factor: 7.794

2.  F-18 flurodeoxyglucose negative, F-18 fluoride accumulating in a brain metastasis in a treated case of carcinoma of the breast.

Authors:  Madhavi Tripathi; Abhinav Jaimini; Namita Singh; Nikunj Jain; Maria D'Souza; Prabhjot Kaur; Dinesh Singh; Rajnish Sharma; Anupam Mondal
Journal:  Clin Nucl Med       Date:  2009-05       Impact factor: 7.794

Review 3.  Ki67 in breast cancer: prognostic and predictive potential.

Authors:  Rinat Yerushalmi; Ryan Woods; Peter M Ravdin; Malcolm M Hayes; Karen A Gelmon
Journal:  Lancet Oncol       Date:  2010-02       Impact factor: 41.316

Review 4.  Peptide receptor imaging and therapy.

Authors:  D Kwekkeboom; E P Krenning; M de Jong
Journal:  J Nucl Med       Date:  2000-10       Impact factor: 10.057

Review 5.  Breast cancer brain metastases.

Authors:  Xiaoyun Cheng; Mien-Chie Hung
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

6.  Rare metastases detected by (68)Ga-somatostatin receptor PET/CT in patients with neuroendocrine tumors.

Authors:  Cecilia Carreras; Harshad R Kulkarni; Richard P Baum
Journal:  Recent Results Cancer Res       Date:  2013

7.  Brain metastases from breast cancer: identification of a high-risk group.

Authors:  A J Evans; J J James; E J Cornford; S Y Chan; H C Burrell; S E Pinder; E Gutteridge; J F R Robertson; J Hornbuckle; K L Cheung
Journal:  Clin Oncol (R Coll Radiol)       Date:  2004-08       Impact factor: 4.126

Review 8.  Gallium-68 PET: a new frontier in receptor cancer imaging.

Authors:  A Al-Nahhas; Z Win; T Szyszko; A Singh; C Nanni; S Fanti; D Rubello
Journal:  Anticancer Res       Date:  2007 Nov-Dec       Impact factor: 2.480

9.  Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry.

Authors:  E C Inwald; M Klinkhammer-Schalke; F Hofstädter; F Zeman; M Koller; M Gerstenhauer; O Ortmann
Journal:  Breast Cancer Res Treat       Date:  2013-05-16       Impact factor: 4.872

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.